KR102866823B1 - 5-아자-4'-티오-2'-데옥시사이티딘의 다형체 - Google Patents

5-아자-4'-티오-2'-데옥시사이티딘의 다형체

Info

Publication number
KR102866823B1
KR102866823B1 KR1020237006092A KR20237006092A KR102866823B1 KR 102866823 B1 KR102866823 B1 KR 102866823B1 KR 1020237006092 A KR1020237006092 A KR 1020237006092A KR 20237006092 A KR20237006092 A KR 20237006092A KR 102866823 B1 KR102866823 B1 KR 102866823B1
Authority
KR
South Korea
Prior art keywords
aza
delete delete
dcyd
crystalline
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237006092A
Other languages
English (en)
Korean (ko)
Other versions
KR20230061354A (ko
Inventor
마크 제이. 수토
두영 정
진수 이
현용 조
Original Assignee
써던 리서취 인스티튜트
주식회사 피노바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 써던 리서취 인스티튜트, 주식회사 피노바이오 filed Critical 써던 리서취 인스티튜트
Publication of KR20230061354A publication Critical patent/KR20230061354A/ko
Application granted granted Critical
Publication of KR102866823B1 publication Critical patent/KR102866823B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237006092A 2020-07-23 2021-07-23 5-아자-4'-티오-2'-데옥시사이티딘의 다형체 Active KR102866823B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055754P 2020-07-23 2020-07-23
US63/055,754 2020-07-23
PCT/US2021/043021 WO2022020747A1 (en) 2020-07-23 2021-07-23 Polymorophs of 5-aza-4'-thio-2-deoxycytidine

Publications (2)

Publication Number Publication Date
KR20230061354A KR20230061354A (ko) 2023-05-08
KR102866823B1 true KR102866823B1 (ko) 2025-09-30

Family

ID=79687860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006092A Active KR102866823B1 (ko) 2020-07-23 2021-07-23 5-아자-4'-티오-2'-데옥시사이티딘의 다형체

Country Status (10)

Country Link
US (1) US11447472B2 (enExample)
EP (1) EP4185583A4 (enExample)
JP (1) JP7679452B2 (enExample)
KR (1) KR102866823B1 (enExample)
CN (1) CN115989229A (enExample)
AU (1) AU2021314329A1 (enExample)
BR (1) BR112023001236A2 (enExample)
CA (1) CA3186696A1 (enExample)
MX (1) MX2023000979A (enExample)
WO (1) WO2022020747A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230123277A1 (en) * 2021-10-15 2023-04-20 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease and thalassemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152459A1 (en) 2018-02-01 2019-08-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN103951583B (zh) * 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2011109012A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
EP3527226A4 (en) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152459A1 (en) 2018-02-01 2019-08-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tiwari et al. Nucleosides, Nucleotides& Nucleic Acids: Vol.22, No. 12, pp2161-2170, 2003*

Also Published As

Publication number Publication date
MX2023000979A (es) 2023-04-20
JP7679452B2 (ja) 2025-05-19
EP4185583A4 (en) 2024-10-30
CA3186696A1 (en) 2022-01-27
EP4185583A1 (en) 2023-05-31
WO2022020747A1 (en) 2022-01-27
US11447472B2 (en) 2022-09-20
AU2021314329A1 (en) 2023-02-23
AU2021314329A8 (en) 2023-03-09
JP2023535724A (ja) 2023-08-21
KR20230061354A (ko) 2023-05-08
WO2022020747A8 (en) 2023-02-16
BR112023001236A2 (pt) 2023-04-04
US20220024903A1 (en) 2022-01-27
CN115989229A (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
EP3552611A1 (en) Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
AU2020222056A1 (en) Crystalline forms of an RSK inhibitor
JP2018505193A (ja) Ｎ−（３，５−ジメトキシフェニル）−ｎ’−（１−メチルエチル）−ｎ−［３−（１−メチル−１ｈ−ピラゾール−４−イル）キノキサリン−６−イル］エタン−１，２−ジアミンを含んでなる医薬組成物
EP3406591B1 (en) Dicaffeoyl-spermidine derivative glycoside and use thereof
US11938123B2 (en) Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers
CN113416199B (zh) 一种石蒜碱β-芳基丙烯酸酯衍生物及其制备方法和用途
KR102866823B1 (ko) 5-아자-4'-티오-2'-데옥시사이티딘의 다형체
CN118021819A (zh) Xpo1抑制剂和mettl3抑制剂联合在制备治疗胃癌的药物中的应用
CN101896477B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
US20150209380A1 (en) Use of cordycepin in manufacture of medicaments for anti-depression
EP3613746B1 (en) Compound of eoc315 mod.i crystal form and preparation method therefor
CN104926804A (zh) 一类具有抗肿瘤作用的化合物、其制备方法和用途
CN102786458B (zh) 吡咯甲酰胺衍生物、其制备方法和用途
CN113993842B (zh) 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途
WO2017086831A1 (ru) Дихлорацетат n1, n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
KR20230113186A (ko) 5-아자-4'-티오-2'-데옥시사이티딘을 함유하는 경구용 제형 및 이의 제조방법
JP2010500387A5 (enExample)
US20250170132A1 (en) Salts and polymorphic forms of menin inhibitors and pharmaceutical compositions thereof
CN103304556B (zh) 含有苯并吡喃的希夫碱类化合物、其制备方法和用途
JP2007302609A (ja) 低酸素性細胞放射線増感剤における放射線増感能の増強剤
CN114681465B (zh) 洛铂-黄酮药物共晶及其制备方法和应用
CN110862428A (zh) 抗肿瘤的表柔新化合物
CN102329326B (zh) 吡咯衍生物、其制备方法和用途
CN103880793A (zh) 含呋喃亚胺类化合物及其制备方法和用途
US8586561B2 (en) Anti-tumor agent comprising cytidine derivative and carboplatin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)